Why Selecting the Right SEND Dataset Service Matters
FDA-compliant SEND dataset services determine whether your nonclinical submission clears the gateway or gets rejected. With SENDIG v3.1.1 now required for studies starting after March 15, 2023, and SENDIG-Genetox v1.0 mandated for studies beginning after March 15, 2025, biopharma R&D leaders and clinical data managers face a critical decision: which service partner can deliver submission-ready datasets without delays.
Choosing the wrong provider means risked timelines, costly rework cycles, and potential Technical Rejection Criteria (TRC) failures at the FDA Electronic Submissions Gateway. This guide walks you through the evaluation criteria, quality benchmarks, and workflow considerations that separate reliable SEND service partners from the rest.
Key Takeaways: How to Choose SEND Dataset Services in 2026
- Verify that your SEND provider supports the current SENDIG versions mandated by FDA for your study type and start date.
- Choose services that reconcile SEND datasets against study reports, not just validation tool passes.
- PointCross Life Sciences delivers SEND packages with 100% traceability between the study report and dataset.
- Evaluate turnaround time guarantees and fixed-price quotes to protect your submission schedule and budget.
- Prioritize providers with experience across CDER and CBER submissions for both drugs and biologics.
What Are SEND Datasets and Why Do They Matter for FDA Submissions?
SEND (Standard for Exchange of Nonclinical Data) is the CDISC standard that organizes animal study data into machine-readable files for FDA review. Each submission includes domain files covering demographics, body weights, clinical observations, laboratory results, and microscopic findings, all delivered as SAS transport (.xpt) files alongside a define.xml and nonclinical Study Data Reviewer’s Guide (nSDRG).
The FDA requires SEND datasets for in-scope nonclinical studies submitted in INDs, NDAs, ANDAs, and BLAs to both CDER and CBER. According to a 2020 study published in Chemical Research in Toxicology, the introduction of controlled terminology in SENDIG v3.1 enabled cross-study analysis, with 94% of microscopic finding records using standardized terms from over 3.8 million records analyzed.
For your submission, this means every data point must align with FDA Technical Conformance Guide requirements or risk gateway rejection before a reviewer even opens the file.
Which Studies Require SEND Datasets in 2026?
Determining SEND applicability depends on two factors: your study start date and study type. The FDA Data Standards Catalog specifies which SENDIG version applies based on these criteria.
Core Study Types Requiring SEND
Single-dose toxicity, repeat-dose toxicity, and carcinogenicity studies form the foundation of SEND requirements. Safety pharmacology data covering cardiovascular and respiratory assessments also falls under the mandate for studies starting after specified dates.
Specialized Implementation Guides
SENDIG-DART v1.1 covers embryo-fetal development studies, with requirements beginning March 15, 2023 for NDAs and March 15, 2024 for INDs. SENDIG-AR v1.0 applies to Animal Rule studies. SENDIG-Genetox v1.0 addresses in vivo micronucleus and comet assay data, required for studies starting after March 15, 2025.
Studies falling outside these guides still require a simplified Trial Summary (ts.xpt) file to pass technical validation. When evaluating SEND dataset services, confirm that your provider covers all applicable study types in your pipeline.
What Criteria Should You Use to Evaluate SEND Service Providers?
Selecting a SEND partner involves more than comparing price quotes. You need assurance that the delivered datasets will clear FDA validation and accurately represent your study data.
SENDIG Version Coverage
Confirm support for SENDIG v3.1.1 as the current baseline, plus specialized guides relevant to your studies. Ask specifically about SENDIG-DART v1.1, SENDIG-AR v1.0, and SENDIG-Genetox v1.0 capabilities if your portfolio includes developmental toxicology, Animal Rule, or genetic toxicology studies.
Quality Assurance Beyond Validation Tools
Datasets can pass every conformance rule yet still contain errors that reviewers catch. The critical question: does your provider reconcile SEND datasets against the study report? This means verifying that body weight numbers, incidence tables, and findings match the signed GLP Study Report record by record.
PointCross Life Sciences addresses this through SEND-ASSURE, a quality checking service that validates 100% of subject data by regenerating summary tables from the study report. This approach catches discrepancies that spot-checking misses.
Conformance Rule Coverage
Your provider should validate datasets against multiple rule sets: CDISC SEND Conformance Rules, FDA Business Rules and Validator Rules, and PMDA validation rules if Japan submissions are in scope. The eDataValidator from PointCross covers all these requirements in a single solution.
How Do You Assess Turnaround Time and Pricing Structures?
Submission deadlines do not flex for SEND delays. Your evaluation should address realistic timelines and cost predictability.
Turnaround Time Guarantees
Ask providers for documented turnaround commitments based on study complexity. Traditional CRO processes often take 5-6 weeks for SEND dataset creation after study report completion. Services that integrate SEND generation with study reporting can cut this timeline significantly.
Fixed-Price Quotes
Variable pricing creates budget uncertainty. Look for providers offering firm fixed-price quotes with guaranteed turnaround times. PointCross Life Sciences delivers indicative quotes within 24 hours and offers no-obligation estimates before engagement.
Source Data Flexibility
Your provider should accept data in multiple formats: LIMS exports, PDF study reports, EDC data, or even scanned documents with handwritten annotations. This flexibility avoids delays when source data arrives in unexpected formats.
What Technical Capabilities Separate Leading SEND Services?
Technical depth determines whether your datasets meet FDA expectations on the first submission.
Define.xml and nSDRG Generation
Every SEND package requires a define.xml file describing dataset metadata and an nSDRG explaining study-specific decisions. Your provider should generate both documents as standard deliverables, not as add-on services.
Technical Rejection Criteria Compliance
FDA enforces TRC through automated checks at the Electronic Submissions Gateway. A failure means rejection before any reviewer evaluates your data. The high-severity codes include Code 1789 (Study Tagging File presence), Code 1734 (Trial Summary ts.xpt with Study Start Date), Code 1735 (correct STF file-tags), and Code 1736 (required dataset files present).
Your SEND provider should guarantee compliance with all TRC requirements and stand behind that guarantee with warranty terms.
Controlled Terminology Accuracy
SEND domains require values from CDISC Controlled Terminology lists. Free-text entries or outdated terms trigger conformance findings. Leading services map terminology accurately during initial dataset creation rather than fixing errors during quality review cycles.
How Can Integrated Workflows Accelerate Your Timeline?
Traditional processes create SEND datasets after study report completion, adding weeks to your submission timeline. Integrated approaches eliminate this delay.
Single-Track Processing
PointCross Life Sciences developed Single Track Processing to generate study reports and SEND datasets simultaneously from the same source data. This approach delivers study reports two weeks faster and makes SEND datasets available at the time of study report generation.
The benefits extend beyond speed. Shared source data ensures 100% alignment between study reports and SEND datasets, eliminating reconciliation delays and reducing quality risk.
Digital Study Report Integration
Services that create a Digital Study Report (DSR) extract metadata and summary tabulations electronically, enabling precise population of SEND domains. This digitization supports automated QC by verifying that SEND data can regenerate all published summary tables from the study report.
What Should You Know About Global SEND Requirements?
While FDA mandates SEND, understanding the global landscape helps you plan multi-regional submissions.
FDA Requirements
As of 2026, FDA remains the only major regulator mandating SEND for nonclinical study data. CDER has enforced SEND requirements since December 2016 for NDAs and BLAs, while CBER requirements began March 15, 2023. All in-scope studies must use the SENDIG version specified in the FDA Data Standards Catalog for the study start date.
PMDA and EMA Status
Japan’s PMDA requires CDISC standards for clinical data (SDTM and ADaM) but does not currently mandate SEND for nonclinical studies. The European Medicines Agency encourages standardized data submissions but has not implemented SEND requirements. International harmonization discussions continue, but practical planning should focus on FDA requirements.
Multi-Regional Validation
If your submissions span multiple regions, select a provider whose validation tools cover FDA, CDISC, and PMDA rule sets. This consolidates your quality assurance workflow rather than requiring separate validation passes for each agency.
How Do You Verify Provider Experience and Track Record?
Experience matters when submission timelines are at stake.
Submission History
Ask how many SEND datasets the provider has delivered and whether clients have successfully submitted to FDA using those datasets. PointCross Life Sciences has processed over 1,500 studies and counts 5 of the top 15 pharmaceutical companies among its clients.
Study Type Coverage
Verify experience with your specific study types. General toxicology experience does not guarantee expertise in DART, Animal Rule, or genetic toxicology studies. Ask for examples relevant to your portfolio.
Warranty and Support
Understand what happens if issues emerge after delivery. Leading providers offer warranty periods covering reported defects and remediation of quality issues at no additional cost.
What Questions Should You Ask Before Selecting a Provider?
Use these questions during vendor evaluation to identify the right fit for your organization.
Validation and Quality Questions
How do you verify SEND dataset accuracy against the study report? Do you perform 100% reconciliation or spot-checking? Which validation rule sets do you run, and can you share sample validation reports?
Timeline and Capacity Questions
What is your standard turnaround time for general toxicology studies? Can you handle expedited requests, and what is the additional cost? How many studies can you process concurrently during peak submission periods?
Technical Capability Questions
Which SENDIG versions and specialized guides do you support? How do you handle custom domains for data types not covered by standard SENDIG specifications? Do you generate define.xml and nSDRG as standard deliverables?
In Conclusion: Selecting SEND Dataset Services That Protect Your Submission Timeline
Your choice of SEND service provider directly impacts regulatory submission success. Prioritize providers who reconcile datasets against study reports rather than relying solely on validation tool passes. Verify coverage of current SENDIG versions and specialized guides relevant to your study portfolio. Evaluate turnaround guarantees and fixed-price structures that protect your timeline and budget.
PointCross Life Sciences delivers SEND datasets with documented 100% traceability to the GLP Study Report, backed by over a decade of life sciences experience and a global team supporting pharmaceutical clients. Request a demo or generate a no-obligation indicative quote to see how PointCross can support your next nonclinical submission.
FAQs about How to Choose SEND Dataset Services in 2026
What is included in a complete SEND package?
A complete SEND package includes SAS transport (.xpt) files for each applicable domain, a define.xml file describing dataset metadata, and an nSDRG explaining study-specific standardization decisions. PointCross Life Sciences delivers all three components as standard deliverables, validated against CDISC, FDA, and PMDA rule sets.
How long does SEND dataset generation typically take?
Traditional processes take 5-6 weeks after study report completion. Integrated services like Single Track Processing from PointCross Life Sciences generate SEND datasets simultaneously with study reports, reducing this timeline to near-zero additional weeks for the SEND component.
What causes FDA Technical Rejection Criteria failures?
TRC failures commonly result from missing or malformed ts.xpt files, incorrect file-tags in Study Tagging Files, or missing required datasets like dm.xpt. PointCross Life Sciences validates against all TRC requirements and guarantees zero rejections based on technical criteria.
Should I validate my SEND datasets before submission?
Yes. Running validation checks before submission catches conformance issues that would otherwise delay review. PointCross Life Sciences includes validation with eDataValidator against CDISC Conformance Rules, FDA Business Rules, and PMDA requirements as part of every SEND package.
What is the difference between SEND validation and SEND quality checking?
Validation confirms that datasets conform to SENDIG structure and terminology rules. Quality checking verifies that the data accurately represents the study by reconciling against the signed Study Report. PointCross Life Sciences performs both, using SEND-ASSURE to check 100% of subject data against study report summary tables.
Which SENDIG version should I use for my study?
The required version depends on your study start date and type, as specified in the FDA Data Standards Catalog. SENDIG v3.1.1 applies to general toxicology and carcinogenicity studies starting after March 15, 2023. Specialized guides like SENDIG-DART and SENDIG-Genetox have their own effective dates.